TY - JOUR
T1 - Non-alcoholic fatty liver disease and mortality among US adults
T2 - Prospective cohort study
AU - Lazo, Mariana
AU - Hernaez, Ruben
AU - Bonekamp, Susanne
AU - Kamel, Ihab R.
AU - Brancati, Frederick L.
AU - Guallar, Eliseo
AU - Clark, Jeanne M.
PY - 2011/12/17
Y1 - 2011/12/17
N2 - Objective: To evaluate the association between non-alcoholic fatty liver disease and all cause and cause specific mortality in a representative sample of the US general population. Design: Prospective cohort study. Setting: US Third National Health and Nutrition Examination Survey (NHANES III: 1988-94) with follow-up of mortality to 2006. Participants: 11 371 adults aged 20-74 participating in the Third National Health and Nutrition Examination Survey, with assessment of hepatic steatosis. Main outcome measure: Mortality from all causes, cardiovascular disease, cancer, and liver disease (up to 18 years of follow-up). Results: The prevalence of non-alcoholic fatty liver disease with and without increased levels of liver enzymes in the population was 3.1% and 16.4%, respectively. Compared with participants without steatosis, those with non-alcoholic fatty liver disease but normal liver enzyme levels had multivariate adjusted hazard ratios for deaths from all causes of 0.92 (95% confidence interval 0.78 to 1.09), from cardiovascular disease of 0.86 (0.67 to 1.12), from cancer of 0.92 (0.67 to 1.27), and from liver disease of 0.64 (0.12 to 3.59). Compared with participants without steatosis, those with non-alcoholic fatty liver disease and increased liver enzyme levels had adjusted hazard ratios for deaths from all causes of 0.80 (0.52 to 1.22), from cardiovascular disease of 0.59 (0.29 to 1.20), from cancer of 0.53 (0.26 to 1.10), and from liver disease of 1.17 (0.15 to 8.93). Conclusions: Non-alcoholic fatty liver disease was not associated with an increased risk of death from all causes, cardiovascular disease, cancer, or liver disease.
AB - Objective: To evaluate the association between non-alcoholic fatty liver disease and all cause and cause specific mortality in a representative sample of the US general population. Design: Prospective cohort study. Setting: US Third National Health and Nutrition Examination Survey (NHANES III: 1988-94) with follow-up of mortality to 2006. Participants: 11 371 adults aged 20-74 participating in the Third National Health and Nutrition Examination Survey, with assessment of hepatic steatosis. Main outcome measure: Mortality from all causes, cardiovascular disease, cancer, and liver disease (up to 18 years of follow-up). Results: The prevalence of non-alcoholic fatty liver disease with and without increased levels of liver enzymes in the population was 3.1% and 16.4%, respectively. Compared with participants without steatosis, those with non-alcoholic fatty liver disease but normal liver enzyme levels had multivariate adjusted hazard ratios for deaths from all causes of 0.92 (95% confidence interval 0.78 to 1.09), from cardiovascular disease of 0.86 (0.67 to 1.12), from cancer of 0.92 (0.67 to 1.27), and from liver disease of 0.64 (0.12 to 3.59). Compared with participants without steatosis, those with non-alcoholic fatty liver disease and increased liver enzyme levels had adjusted hazard ratios for deaths from all causes of 0.80 (0.52 to 1.22), from cardiovascular disease of 0.59 (0.29 to 1.20), from cancer of 0.53 (0.26 to 1.10), and from liver disease of 1.17 (0.15 to 8.93). Conclusions: Non-alcoholic fatty liver disease was not associated with an increased risk of death from all causes, cardiovascular disease, cancer, or liver disease.
UR - http://www.scopus.com/inward/record.url?scp=83755178774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=83755178774&partnerID=8YFLogxK
U2 - 10.1136/bmj.d6891
DO - 10.1136/bmj.d6891
M3 - Article
C2 - 22102439
AN - SCOPUS:83755178774
SN - 0959-8146
VL - 343
SP - 1245
JO - BMJ (Online)
JF - BMJ (Online)
IS - 7836
M1 - d6891
ER -